Enhancing COVID-19 Vaccine Efficacy: Dual Adjuvant Strategies with TLR7/8 Agonists and Glycolipids
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Ke Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, Hubei, P. R. China. Hauptthemen laut MEDLINE: Toll-Like Receptor 8, Toll-Like Receptor 7, COVID-19 Vaccines, Adjuvants, Immunologic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Higher Education Discipline Innovation Project.
Abstract (Originalsprache)
The controlled release of immunostimulatory agents represents a promising strategy to enhance vaccine efficacy while minimizing side effects. This study aimed to improve the efficacy of the RBD-Fc-based COVID-19 vaccine through combining of an iNKT cell agonist and a TLR7/8 agonist using covalent conjugation and temporal delivery. We hypothesized that these combinations would yield a more balanced Th1/Th2 immune response. For covalent conjugation, we employed an uncleavable linker and a self-immolative disulfide linker to conjugate α-galactosylceramide (αGC) to imidazoquinoline (IMDQ). The αGC-SS-IMDQ-Ac conjugate, designed with a prodrug strategy for controlled TLR7/8 agonist release, elicited a higher IFN-γ/IL-4 T cell response ratio than individual adjuvants or their admixture. In the temporal delivery approach, administering IMDQ followed by αGC after 2 h resulted in the highest IgG2a/IgG1 ratio, significantly surpassing other groups. A 6 h delay between glycolipid and IMDQ injections yielded balanced IgG responses, enhancing IgG, IgG1, and IgG2a levels synergistically.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, Hubei, P. R. China.
- National Key Laboratory of Green Pesticide, Hubei International Scientific and Technological Cooperation Base of Pesticide and Green Synthesis, International Joint Research Center for Intelligent Biosensing Technology a…
ORCID-Profile: Zheng Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Higher Education Discipline Innovation Project
Zitieren
APA
Li, K., Hu, X., Tu, X. Y., Xian, M. Y., Huang, L. L., Huang, T., Luo, R., Jin, H., & Liu, Z. (2024). Enhancing COVID-19 Vaccine Efficacy: Dual Adjuvant Strategies with TLR7/8 Agonists and Glycolipids. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01801
Vancouver
Li K, Hu X, Tu XY, Xian MY, Huang LL, Huang T, et al. Enhancing COVID-19 Vaccine Efficacy: Dual Adjuvant Strategies with TLR7/8 Agonists and Glycolipids. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01801
BibTeX
@article{Li2024,
author = {Li, Ke and Hu, Xing and Tu, Xin-Yi and Xian, Mao-Ying and Huang, Lei-Lei and Huang, Ting and Luo, Rui and Jin, Hui and Liu, Zheng},
title = {Enhancing COVID-19 Vaccine Efficacy: Dual Adjuvant Strategies with TLR7/8 Agonists and Glycolipids},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01801}
}
EUVIMED